When is imaging needed to assess the response to treatment in cardiac amyloidosis

Cardiac amyloidosis is characterized by systolic and diastolic abnormalities due to deposition of amyloid fibril within the myocardial extracellular space. Technological advances in multimodality cardiac imaging now helps in accurate diagnosis and prognosis of this disease. With technological advances in imaging, it is now easier to follow up these patients whether they are getting response to therapy.

Left ventricular global longitudinal strain assessment is an important noninvasive tool to track response to treatment in cardiac amyloidosis patient.

Present era has shown the importance of using multimodality imaging to understand the pathophysiology of this disease which has been supplemented by both imaging and blood biomarkers. These help in prognosticating the disease burden and to assess treatment response. Future research is now focused on the use of artificial intelligence and precision medicine to detect of changes earlier in the course of treatment.